Histologic transformation to high-grade neuroendocrine carcinoma—including small cell carcinoma—develops as a resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) in approximately 3% to 4% of patients with EGFR-mutant NSCLC.1 Here, EGFR is linked to neuroendocrine carcinoma.